meta|evidence COVID-19

Living systematic review and meta-analysis

adjuvant therapies
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
anti GM-CSF
clarithromycine
colchicine
Colchicine plus rosuvastatin
mepolizumab
naproxen, ibuprofen
non-steroidal anti-inflammatory drugs
selinexor
sodium aescinate
stem cells
tradipitant
vilobelimab (IFX-1)
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins

potential COVID-19 treatments
control
placebo
standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention

Studies
Mapping
Meta-analysis
Excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -